CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The use of thalidomide analogs, specifically lenalidomide, has been linked to an increased risk of TP53-mutated myeloid neoplasms. Furthermore, lenalidomide, but not pomalidomide, causes the expansion of preleukemic Trp53-mutant HSPCs via selective Ck1 degradation.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
